The use of anti-PAD4 molecules—such as Calcium, rTcpC, JBI-589, GSK199, GSK484, and TDFA—has been proposed as a means to reduce NETosis, which in turn could mitigate the clinical impact of one of the most severe complications of sepsis: acute respiratory distress syndrome (ARDS) [82]. Here, PADI4 is linked to acute respiratory distress syndrome.